29 results
Our main goal is to establish whether there is difference in the effect between the use of aspirin, dualtherapy aspirin/clopidogrel, or ticagrelor on the occurrence of atherothrombotic events in patients following lower extremity peripheral…
To demonstrate elevation in immune responsiveness to LPS stimulation when switching from ASA to DPI in patients with CAD, and to further explore whether changes in monocyte function and epigenetic landscape are responsible for the observed…
The main purpose of this study is to assess the hypothesis that a strategy with ASA 100mg/day and intensive blood pressure treatment (targeted systolic blood pressure below 120mmHg) with advice to patients to do weekly measurements using a home…
The Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients (LEGACY) trial will investigate whether omitting aspirin reduces the rate of major or minor bleeding while remaining non-inferior to the current…
To demonstrate that oral anticoagulation with the NOAC edoxaban is superior to current therapy (antiplatelet therapy or no therapy depending on cardio-vascular risk) to prevent stroke, systemic embolism, or cardiovascular death in patients with AHRE…
The aim of this comparative effectiveness research is to determine the effect of intake of aspirin before bedtime in comparison with aspirin on awakening in patients already using aspirin for secondary prevention of CVD. Our primary objective will…
To evaluate safety, tolerability pharmacokinetic profile; to explore pharmacodynamics; to evaluate major effects of Guanabenz on quantitative MRI and clinical parameters in pediatric patients with VWM; explore biomarkers in blood and cerebrospinal…
The primary objective of this study is to assess the feasibility and safety of a single antiplatelet strategy with prasugrel or ticagrelor prior to, during and after PCI with a new generation drug-eluting in non-ST-elevation acute coronary syndrome…
To assess whether and to what extent dual therapy clopidogrel 75 mg/acetylsalicylic acid 80 mg daily is superior to monotherapy clopidogrel 75 mg daily, in reducing the combined endpoint all-cause death and cardiovascular adverse events after one-…